References 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71–96. 2. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B (2003) Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101: 885–891. 3. Berkel H, Holcombe RF, Middlebrooks M, Kannan K (1996) Nonsteroidal antiinflammatory drugs and colorectal cancer. Epidemiol Rev 18: 205–217. 4. Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, et al. (1999) The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 29: 72–76. 5. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, et al. (1998) Over-the-counter analgesics and risk of ovarian cancer. Lancet 351: 104–107. 6. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM (2008) Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 98: 1781–1783. 7. Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, et al. (2002) Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 8: 202–209. 8. Lacey JV, Jr., Sherman ME, Hartge P, Schatzkin A, Schairer C (2004) Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 108: 281–286. 9. Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE (2009) Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol 169: 1378–1387. 10. Vane JR, Botting RM (1998) Mechanism of action of antiinflammatory drugs. Int J Tissue React 20: 3–15. 11. Dore M, Cote LC, Mitchell A, Sirois J (1998) Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. J Histochem Cytochem 46: 77–84. 12. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, et al. (2003) Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 63: 906–911. 13. Klimp AH, Hollema H, Kempinga C, van der Zee AG, de Vries EG, et al. (2001) Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res 61: 7305–7309. 14. Matsumoto Y, Ishiko O, Deguchi M, Nakagawa E, Ogita S (2001) Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int J Mol Med 8: 31–36. 15. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, et al. (1995) Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87: 506–516. 16. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, et al. (1996) Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 74: 1105–1115. 17. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, et al. (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80: 98–106. 18. Urick ME, Giles JR, Johnson PA (2008) VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer. Gynecol Oncol 110: 418–424. 19. Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153: 1249–1256. 20. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, et al. (1995) Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 55: 360–368. 21. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, et al. (2003) Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9: 5721–5728. 22. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB (1995) Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 11: 2477–2486. 23. Zerbini LF, Czibere A, Wang Y, Correa RG, Otu H, et al. (2006) A novel pathway involving melanoma differentiation associated gene-7/interleukin-24 mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth arrest of cancer cells. Cancer Res 66: 11922–11931. 24. Vairapandi M, Balliet AG, Hoffman B, Liebermann DA (2002) GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress. J Cell Physiol 192: 327–338. 25. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, et al. (2001) Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 20: 7051–7063. 26. Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, et al. (2009) Historical perspective and recent insights into our understanding of the molecular and NSAIDs and NF-kB Inhibitors in Ovarian Cancer biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther 8: 391–400. 27. Dash R, Bhutia SK, Azab B, Su ZZ, Quinn BA, et al. (2010) mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev 21: 381–391. 28. Emdad L, Sarkar D, Lebedeva IV, Su ZZ, Gupta P, et al. (2006) Ionizing radiation enhances adenoviral vector expressing mda-7/IL-24-mediated apop- tosis in human ovarian cancer. J Cell Physiol 208: 298–306. 29. Yacoub A, Liu R, Park MA, Hamed HA, Dash R, et al. (2010) Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95- dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells. Mol Pharmacol 77: 298–310. 30. Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725–734. 31. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301–310. 32. Zerbini LF, Wang Y, Cho JY, Libermann TA (2003) Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 63: 2206–2215. 33. Baldwin AS (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107: 241–246. 34. Zerbini LF, Wang Y, Czibere A, Correa RG, Cho JY, et al. (2004) NF-kappa B- mediated repression of growth arrest- and DNA-damage-inducible proteins 45alpha and gamma is essential for cancer cell survival. Proc Natl Acad Sci U S A 101: 13618–13623. 35. Carlin JR, Hoglund P, Eriksson LO, Christofalo P, Gregoire SL, et al. (1992) Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. Drug Metab Dispos 20: 148–155. 36. Davies NM, McLachlan AJ, Day RO, Williams KM (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo- oxygenase-2 inhibitor. Clin Pharmacokinet 38: 225–242. 37. Kennedy JM, van Rij AM (2006) Drug absorption from the small intestine in immediate postoperative patients. Br J Anaesth 97: 171–180. 38. Liu XH, Yao S, Kirschenbaum A, Levine AC (1998) NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58: 4245–4249. 39. Su SF, Chou CH, Kung CF, Huang JD (2003) In vitro and in vivo comparison of two diclofenac sodium sustained release oral formulations. Int J Pharm 260: 39–46. 40. Terlinden R, Feige M, Romer A (1988) Determination of the two major metabolites of ebselen in human plasma by high-performance liquid chroma- tography. J Chromatogr 430: 438–442. 41. Khosravan R, Wu JT, Joseph-Ridge N, Vernillet L (2006) Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol 46: 855–866. 42. Lentjes EG, van Ginneken CA (1987) Pharmacokinetics of flufenamic acid in man. Int J Clin Pharmacol Ther Toxicol 25: 185–187. 43. Lockwood GF, Albert KS, Gillespie WR, Bole GG, Harkcom TM, et al. (1983) Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships. Clin Pharmacol Ther 34: 97–103. 44. Ravis WR, Diskin CJ, Campagna KD, Clark CR, McMillian CL (1993) Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure. J Clin Pharmacol 33: 527–534. 45. Ray GF, Lanman RC, Fu CJ, Paranka NS, Pamukcu R, et al. (1995) Determination of FGN-1 (an active metabolite of sulindac) in human plasma, urine, and feces by HPLC. J Pharm Biomed Anal 14: 213–220. 46. Roberts DG, Gerber JG, Barnes JS, Zerbe GO, Nies AS (1985) Sulindac is not renal sparing in man. Clin Pharmacol Ther 38: 258–265. 47. Skjodt NM, Davies NM (1999) Clinical pharmacokinetics and pharmacody- namics of bromfenac. Clin Pharmacokinet 36: 399–408. 48. Swanson BN, Boppana VK, Vlasses PH, Holmes GI, Monsell K, et al. (1982) Sulindac disposition when given once and twice daily. Clin Pharmacol Ther 32: 397–403. 49. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396: 77–80. 50. Oida Y, Gopalan B, Miyahara R, Inoue S, Branch CD, et al. (2005) Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther 4: 291–304. 51. Lebedeva IV, Su ZZ, Sarkar D, Gopalkrishnan RV, Waxman S, et al. (2005) Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis. Onco- gene 24: 585–596. 52. Mita H, Tsutsui J, Takekawa M, Witten EA, Saito H (2002) Regulation of MTK1/MEKK4 kinase activity by its N-terminal autoinhibitory domain and GADD45 binding. Mol Cell Biol 22: 4544–4555. 53. Tobe M, Isobe Y, Tomizawa H, Nagasaki T, Takahashi H, et al. (2003) A novel structural class of potent inhibitors of NF-kappa B activation: structure-activity relationships and biological effects of 6-aminoquinazoline derivatives. Bioorganic & medicinal chemistry 11: 3869–3878. 54. Lyss G, Knorre A, Schmidt TJ, Pahl HL, Merfort I (1998) The anti- inflammatory sesquiterpene lactone helenalin inhibits the transcription factor PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24285